Resource Summary Report

Generated by NIF on Sep 23, 2026

A-172

RRID:CVCL_0131
Type: Cell Line

Proper Citation

RRID:CVCL_0131

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0131

Proper Citation: RRID:CVCL_0131

Description: Cell line A-172 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Glioblastoma

Defining Citation: PMID:77569, PMID:212188, PMID:450131, PMID:833871, PMID:1255758, PMID:1385192, PMID:3518877, PMID:3675803, PMID:3759084, PMID:4357758, PMID:6173755, PMID:6220172, PMID:6256643, PMID:6260907, PMID:6652614, PMID:6825208, PMID:6954533, PMID:7523863, PMID:9090379, PMID:9220028, PMID:9290701, PMID:9842975, PMID:10402232, PMID:10416987, PMID:10698499, PMID:11351043, PMID:14614447, PMID:14655754, PMID:15900046, PMID:16232199, PMID:16697959, PMID:17254797, PMID:17595512, PMID:19365568, PMID:19435942, PMID:20164919, PMID:20215515, PMID:21406405, PMID:22460905, PMID:22570425, PMID:23637631, PMID:25485619, PMID:25877200, PMID:25984343, PMID:26589293, PMID:27397505, PMID:30188626, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:34036375, PMID:35839778

Comments: Population: Caucasian., Part of: PTEN genetic alteration cell panel (ATCC TCP-1030)., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: A-172

Synonyms: A172, A 172, A-172 MG, A-172MG

Cross References: BTO:BTO_0000016, CLO:CLO_0001543, CLO:CLO_0001559, CLO:CLO_0001560, CLO:CLO_0050637, EFO:EFO_0002101, MCCL:MCC:0000023, CLDB:cl142, CLDB:cl143, CLDB:cl144, CLDB:cl146, AddexBio:C0005009/5018, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1620, ATCC:CRL-7899, BioGRID_ORCS_Cell_line:823, BioSample:SAMN03471115, BioSample:SAMN03471212, BioSample:SAMN03471659, BioSample:SAMN03471918, BioSample:SAMN10988258, cancercelllines:CVCL_0131, CCRID:3101HUMTCHu171, Cell_Model_Passport:SIDM00799, CGH-DB:138-1, ChEMBL-Cells:CHEMBL3308491, ChEMBL-Targets:CHEMBL614512, CLS:300108, Cosmic:687563, Cosmic:849883, Cosmic:897446, Cosmic:1014068, Cosmic:1036334, Cosmic:1066233, Cosmic:1171223, Cosmic:1236360, Cosmic:1610751, Cosmic:1746956, Cosmic:1995327, Cosmic:2302321, Cosmic:2367506, Cosmic:2516012, Cosmic-CLP:687563, DepMap:ACH-000558, ECACC:88062428, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS225AJI, ENCODE:ENCBS874LTK, FANTOM5_SSTAR:10444-106F3, GDSC:687563, GEO:GSM101609, GEO:GSM101610, GEO:GSM326244, GEO:GSM886850, GEO:GSM887914, GEO:GSM1374378, GEO:GSM1669577, IARC_TP53:21157, ICLC:HTL97013, IGRhCellID:A172, IZSLER:BS TCL 2, JCRB:JCRB0228, KCB:KCB 200966YJ, KCLB:21620, LiGeA:CCLE_757, LINCS_LDP:LCL-1348, Lonza:178, NCBI_Iran:C211, PharmacoDB:A172_36_2019, PRIDE:PXD001110, PRIDE:PXD030304, Progenetix:CVCL_0131, PubChem_Cell_line:CVCL_0131, RCB:RCB2530, TKG:TKG 0183, Wikidata:Q54605968

ID: CVCL_0131

Record Creation Time: 20220427T215104+0000

Record Last Update: 20260920T011707+0000

Ratings and Alerts

No rating or validation information has been found for A-172.

Warning: Discontinued: ATCC; CRL-7899
Population: Caucasian., Part of: PTEN genetic alteration cell panel (ATCC TCP-1030)., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 604 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Zhang Z, et al. (2026) B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression. Molecular biomedicine, 7(1).

Zhang Z, et al. (2026) Machine learning model on multi-omics data enables risk stratification and identifies molecular heterogeneity and therapeutic targets in glioblastoma. Molecular cancer, 25(1).

Fang C, et al. (2026) CUDC-907 inhibits glioblastoma and enhances glioblastoma sensitivity to temozolomide by inhibiting DNA damage repair. Genes & diseases, 13(5), 101948.

Kucwaj-Brysz K, et al. (2026) Spirohydantoin derivatives exert dopamine D2-like receptor-independent cytotoxicity in glioblastoma cells with possible involvement of calpain inhibition. Scientific reports, 16(1).

Song J, et al. (2026) JOSD1 Deubiquitinates Twist1 and Facilitates Epithelial-Mesenchymal Transition in Glioblastoma. Cell biochemistry and function, 44(4), e70208.

Kempynck N, et al. (2026) CREsted: modeling genomic and synthetic cell-type-specific enhancers across tissues and species. Nature methods, 23(5), 946.

Sidhu RS, et al. (2026) Rap1b promotes glioma growth and stemness via regulation of Notch1 and VEGFR2 signaling pathways. Cellular signalling, 143, 112457.

Krygier K, et al. (2026) A covalent peptide engager approach to equip immunotherapeutic monoclonal and pan IgG serum antibodies with new tumour-targeting function. British journal of pharmacology.

Guo S, et al. (2025) RNA Sequencing Identifies Novel Signaling Pathways and Potential Drug Target Genes Induced by FOSL1 in Glioma Progression and Stemness. Biologics : targets & therapy, 19, 157.

Ramar V, et al. (2025) TRIM21 functions as an oncogene in glioblastoma by transactivating FOSL1 and promoting the ubiquitination of p27. Cell communication and signaling : CCS, 23(1), 313.

Beckner ME, et al. (2025) Cell Settling, Migration, and Stochastic Cancer Gene Expression Suggest Potassium Membrane Flux May Initiate pH Reversal. Biomolecules, 15(8).

Knoll N, et al. (2025) CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer. Cancer research, 85(18), 3518.

Schwarzenbach C, et al. (2025) Therapy-induced senescence of glioblastoma cells is determined by the p21CIP1-CDK1/2 axis and does not require activation of DREAM. Cell death & disease, 16(1), 357.

Yang M, et al. (2025) The alternatively spliced diacylglycerol kinase gamma-? exon13 transcript generated under hypoxia promotes glioblastoma progression. Oncology research, 33(5), 1189.

Shin S, et al. (2025) mTOR inhibition reprograms cellular lipid homeostasis by inducing alternative lipid uptake and promoting cholesterol transport. Molecular cell, 85(18), 3486.

Weber AF, et al. (2025) Downregulation of miR-27a-3p Modulates TGF-? Signaling and Dysregulates Metabolism in Glioblastoma. International journal of molecular sciences, 26(17).

He X, et al. (2025) PI3K? functions as a protein kinase to promote cellular protein O-GlcNAcylation and acetyl-CoA production for tumor growth. Molecular cell, 85(7), 1411.

Yang H, et al. (2025) 7 I, a structurally modified sinomenine, exerts dual anti-GBM effects by inhibiting glioblastoma proliferation and inducing necroptosis which further mediates lysosomal cell death. British journal of pharmacology, 182(10), 2310.

Cornelissen FMG, et al. (2025) Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype. Molecular cancer therapeutics, 24(12), 1878.

Chen K, et al. (2025) Ferroptosis resistance-related TEP1 as a novel prognostic biomarker involved in immune cell infiltration and tumour progression in glioblastoma. Cancer cell international, 26(1), 14.